十三、预后
GD总体预后良好。ATD治疗的缓解率差异很大，为20%～60%。男性、吸烟者（尤其男性）以及甲状腺肿大≥80g的患者的缓解率较低。TRAb的持续高水平以及多普勒彩超显示甲状腺血流增加与复发率高相关。131I和手术治疗的缓解率高于ATD，复发率低于ATD，但是，永久性甲减的发生率高于ATD。偶见没有及时发现和积极治疗的甲亢导致机体多系统受损，特别是心脏受累，或由于某些诱因导致甲状腺危象发生，可以导致死亡。
GD 的自然病程。GD甲亢的自然病程多样，难以预测。Wiersinga认为GD自然病程有如下特点：不缓解的病例占＜10%；反复发作的病例占60%～70%；仅有一次发作的病例占30%～40%。对Graves病20年的随访研究发现，27%的患者治愈；62%的患者反复发作；8%患者亚临床甲亢；3%患者发生甲减[85]。有些患者甲亢，在几年之内变为甲减，然后又转变为甲亢。
参考文献
[1]葛均波，徐永健.内科学[M].9版.北京：人民卫生出版社， 2018.
[2]王辰，王建安.内科学[M].9版.北京：人民卫生出版社，2016.
[3] Melmed S, Polonsky K S, Larsen P R，et al.Williams Textbook of Endocrinology [M].12th Edition.Elsevier,2015.
[4] Hollowell J G, Staehling N W, Flanders W D, et al．Serum TSH, T (4), and thyroid antibodies in the United States p opulation (1988 to 1994):National Health and Nutrition Examination Survey (NHANESⅢ)[J]．J Clin Endocrinol Metab, 2002, 87(2):489-499．
[5] Michele Marino, Paolo Vitti, and Luca.Chiovato Graves’Disease[M].In DeGroot Endocrinology (7th Edition).Elsevier，2015.
[6] Graves R J.New observed affection of the thyroid gland in females.（clinical lecture）[J].Lond Med Surg J （Renshaw）,1835, 7:516-517.
[7] Adams D D，Purves A E.Abnormal responses in the assay of thyrotropins[J].Proc Univ Otago Sch Med, 1956, 34:11-12.
[8] Meek J C, Jones A E, Lewis U J, et al.Characterization of long-acting thyroid stimulator of Graves disease[J].Proc Natl Acad Sci USA, 1964, 52:342-349.
[9] Rapoport B, Chazenbalk G D, Jaume J C, et al.The thyrotropin receptor: interaction with thyrotropin and autoantinodies[J].Endoc Rev, 1998, 19:673-716.
[10] Nystrom H F, Jansson S, Berg G.Incidence rate and clinical features of hyperthyroidism in a long-Term iodine sufficient area of Sweden(Gothenburg) 2003-2005[J].Clin Endocrinol (Oxf), 2013, 78(5):768-776.
[11] McLeod, Donald S.A，Cooper, et al.The incidence and prevalence of thyroid autoimmunity[J].Endocrine, 2012,42(2):252-265.
[12] Furszyfer J, Kurland L T, McConahey W M, et al.Graves’disease in Olmsted County, Minnesota,1935 through 1967[J]．Mayo Clin Proc,1970, 45(9):636-644.
[13] Vanderpump M P, Tunbridge W M, French J M, et al.The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey[J].Clin Endocrinol (Oxf)., 1995, 43:55-68.
[14] McLeod D S, Caturegli P, Cooper D S, et al．Variation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel[J].JAMA, 2014, 311(15):1563-1565.
[15] Carlé A, Pedersen I B, Knudsen N, et al.Epidemiology of subtypes of hyperthyroidism in Denmark: a populationbased study[J].Eur J Endocrinol, 2011, 164: 801-809.
[16] Haraldsson A, Gudmundsson ST,Larusson G, et al.Thyrotoxicosis in Iceland 1980—1982.An epidemiological survey[J].Acta Med Scand, 1985,17(3):253-258.
[17] Nyström H F, Jansson S, Berg G.Incidence Rate and Clinical features of Hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003—2005[J].Clin Endocrinol (Oxf), 2013, 78:768-776.
[18] Kowski F G, Monika B B, M a T, et al.Increased prevalence of hyperthyroidism as an early and transient side-effect of implementing iodine prophylaxis[J].Public health nutrition, 2007, 10(8):799-802.
[19] Laurberg P, Cerqueira C, Ovesen L, et al.Iodine intake as a determinant of thyroid disorders in populations[J].Best Pract Res Clin Endocrinol Metab, 2010, 24: 13-27.
[20] Michael B Zimmermann, Kristien Boelaert.Iodine defi ciency and thyroid disorders[J].Lancet Diabetes Endocrinol, 2015, 3: 286-295.
[21] Teng W, Shan Z, Teng X, et al .Effect of iodine intake on thyroid diseases in China[J].N Engl J Med, 2006,354:2783-2793.
[22] Fan Yang.Epidemiological survey on the relationship between different iodine intakes and prevalence of hyperthyroidism[J].Eur J Endocrinol, 2002, 146：613-618.
[23] Laurberg P, Pedersen K M, Vestergaard H,et al.High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs.high incidence of Graves’ disease in the young in a high iodine intake area: Comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland[J].J Intern Med,1991, 229:415-420.
[24] Li YZ T D, Ba J.Efficacy and safety of longterm universal salt iodization on thyroid disorders:epidemiological evidence from 31 provinces of mainland China[J].Thyroid, 2019, in press.
[25] Villanueva R, Greenberg D A, Davies T F, et al.Sibling recurrence risk in autoimmune thyroid disease[J].Thyroid, 2003,13:761-764.
[26] Jacobson E M, Tomer Y.The genetic basis of thyroid autoimmunity[J].Thyroid, 2007, 17:949-961.
[27] Dittmar M, Libich C, Brenzel T, et al.Increased familial clustering of autoimmune thyroid diseases[J].Horm Metab Res, 2011, 43:200-204.
[28] Davies T F, Latif R, Yin X.New genetic insights from autoimmune thyroid disease[J].J Thyroid Res, 2012,623852.
[29] Tomer Y.Mechanisms of autoimmune thyroid diseases:from genetics to epigenetics[J].Annu Rev Pathol, 2014, 9:147-156.
[30] Velaga MR, Wilson V, Jennings C E, et al.The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase(LYP) gene is a major determinant of Graves’disease[J].J Clin Endocrinol Metab, 2004, 89:5862-5865.
[31] Criswell L A, Pfeiffer K A, Lum R F, et al.Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes[J].Am J Hum Genet, 2005, 76:561-571.
[32] Simmonds M J, Heward J M, Carr-Smith J, et al.Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves’disease[J].J Clin Endocrinol Metab, 2006, 91:1056-1061.
[33] Ban Y, Greenberg D A, Concepcion E, et al.Amino acid substi¬tutions in the thyroglobulin gene are associated with susceptibil¬ity to human and murine autoimmune thyroid disease[J].Proc Natl Acad Sci U S A, 2003,100:15119-15124.
[34] Jin Y, Teng W, Ben S, et al.Genome-wide scan of Graves’ disease: Evidence for linkage on chromosome 5q31 in Chinese Han pedigrees[J].J Clin Endocrinol Metab, 2003, 88(4):1798-1803.
[35] Yang Y, Lingling S, Ying J, et al.Association study between the IL4, IL13, IRF1 and UGRP1 genes in chromosomal 5q31 region and Chinese Graves’disease[J].J Hum Genet, 2005, 50(11):574-582.
[36] Hou X, Mao J Y, Teng W P.Association Studies of The SLC22A4 gene with Graves’disease in Chinese Han Population[M].14th International thyroid congress.Poster, 2010.
[37] Li J, Teng W.Linkage Analysis of the Chromosome 5q31-33 Region Identifies JAKMIP2 as a Risk Factor for Graves'Disease in the Chinese Han Population[J].Med Sci Monit, 2019, 25:1439-1451.
[38] Hou X, Li Y, Li J, et al.Development of thyroid dysfunction and autoantibodies in Graves’multiplex families: an eight-year follow-up study in Chinese Han pedigrees[J].Thyroid, 2011, 21:1353-1358.
[39] Qingling Guo.Alterations of Global DNA Methylation and DNA Methyltransferase Expression in T and B Lymphocytes from Patients with Newly Diagnosed Autoimmune Thyroid Diseases After Treatment: A Follow-Up Study[J].Thyroid, 2018,28(3):377-385.
[40] Xun Chu, Chun-Ming Pan, Shuang-Xia Zhao, et al.A genome-wide association study identifies two new risk loci for Graves’disease[J].Nature Genetics,2011,43(9):897-902.
[41] Brix T H, Hansen P S, Hegedüs L, et al.Too early to dismiss Yersinia enterocolitica infection in the aetiology of Graves’disease.Evidence from a twin case-control study[J].Clin Endocrinol, 2008, 69:491-496.(https://www.daowen.com)
[42] Bech K.Yersinia enterocolitica and thyroid autoimmunity[J].Autoimmunity, 1990, 7:291-294.
[43] Luo G, Fan J L, Seetharamaiah G S, et al.Immunization of mice with Yersinia enterocolitica leads to the induction of antithyrotropin receptor antibodies[J].J Immunol, 1993,151:922-928.
[44] Fierabracci A, Upton C P, Hajibagheri N, et al.Lack of detection of retroviral particles (HIAP-1) in the H9 T cell line co-cultured with thyrocytes of Graves’ disease[J].J Autoimmunity, 2001, 16:457-462.
[45] Bartalena L, Bogazzi F, Chiovato L, et al.2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction[J].Eur Thyroid J, 2018, 7:55-66.
[46] Weetman A P.Immunity, thyroid function and pregnancy:molecular mechanisms[J].Nat Rev Endocrinol, 2010,6:311-318.
[47] Tomer Y, Davies T F.Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function[J].Endocrine Rev, 2003, 24:694-717.
[48] Fugazzola L, Cirello V, Beck-Peccoz P.Microchimerism and endocrine disorders[J].J Clin Endocrinol Metab,2012, 97:1452-1461.
[49] Yin X, Latif R, Tomer Y, et al.Thyroid epigenetics: X chromosome inactivation in patients with autoimmune thyroid disease[J].Ann N Y Acad Sci, 2007, 1110:193-200.
[50] Effraimidis G , Wiersinga W M.Mechanisms in endocrinology: autoimmune thyroid disease: old and new players[J].European journal of endocrinology,2014,170(6):R241-252.
[51] Wu Q, Rayman M P, Lv H, et al.Low population seleniumstatus is associated with increased prevalence of thyroid disease[J].J Clin Endocrinol Metab,2015,100:4037-4047.
[52] Fan Y, X u S, Zhang H, et al.Selenium supplementation for autoimmune thyroiditis: a systematic review and meta-analysis[J].Int J Endocrinol, 2014, 1:904573.
[53] Wichman J, Winther K H, Bonnema S J, et al.Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta-analysis[J].Thyroid, 2016, 26:1681-1692.
[54] Wang W W, Mao J Y, Zhao J J, et al.Decreased Thyroid Peroxidase Antibody Titer in Response to Selenium Supplementation in Autoimmune Thyroiditis and the Influence of a Selenoprotein P Gene Polymorphism: A Prospective, Multicenter Study in China[J].Thyroid,2018, 28(12): 1674-1681.
[55] Marcocci, C，Kahaly, G，Krassas, G E, et al.Selenium and the Course of Mild Graves’ Orbitopathy[J].N Engl J Med, 2011, 364:192031.
[56] Wang J, Lv, S，Chen, G, et al.Meta-Analysis of the Association between Vitamin D and Autoimmune Thyroid Disease[J].Nutrients, 2015,7(4):2485-2498.
[57] Monzani F, Del Guerra P, Caraccio N, et al.Appearance of Graves’ disease after percutaneous ethanol injection for the treatment of hyperfunctioning thyroid adenoma[J].J Endocrinol Invest, 1997, 20:294-298.
[58] Chiovato L, Santini F, Vitti P, et al.Appearance of thyroid stimulating antibody and Graves’ disease after radioiodine therapy for toxic nodular goitre[J].Clin Endocrinol (Oxf),1994, 40:803-806.
[59] Kim M, Moon S, Oh B, et al.Association between perfluoroalkyl substances exposure and thyroid function in adults: A meta-analysis[J].PloS one, 2018, 13(5):e0197244.
[60] Rapoport B and McLachian.TSH receptor cleavage into subunits and shedding of A-subunit and clinical perspective[J].Endoc Rev, 2016, 37: 114-134.
[61] Terry J.Smith, Laszlo Hegedüs.Graves’Disease[J].N Engl J Med, 2016, 375:1552-1565.
[62] Morshed S A, Latif R, Davies TF.Delineating the autoimmune mechanisms in Graves’disease[J].Immunol Res, 2012, 54:191-203.
[63] Mao C, Wang S, Xiao Y, et al.Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves’disease[J].J Immunol, 2011, 186:4734-4743.
[64] Rotondi M, Chiovato L, Romagnani S, et al.Role of chemokines in endocrine autoimmune diseases[J].Endocr Rev, 2007, 28:492-520.
[65] 段然，李静.甲状腺功能亢进症合并肝损害的鉴别诊断和处理[J].中国实用内科杂志.2018，38（10）：971-973.
[66] Wang L, Chen C, Fu J, et al.Effects of sex steroid hormones, thyroid hormone levels, and insulin regulation on thyrotoxic periodic paralysis in Chinese men[J].Endocrine, 2010, 38: 386-390.
[67] Uzma Haider, Patrick Richards, Andrew G.Gianoukakis.Thymic Hyperplasia Associated with Graves’Disease:Pathophysiology and Proposed Management Algorithm[J].Thyroid, 2017, 27(8):994-1000.
[68] Douglas S.Ross, Henry B.Burch, David S.Cooper, et al.2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis[J].Thyroid, 2016, 26(10):1343-1421.
[69] Kummer S, Hermsen D, Distelmaier F.Biotin treatnebt mimick Graves disease[J].N Engl J Med, 2016, 375:704-706.
[70] Kotwal A and Stan M.Thyrotropin receptor antibodyan overview[J].Ophthalmic plast recondtr Surg.2018,34:S20-S27.
[71] Brit J P, Schilz S, Singh O N, et al.Antithyroid Drugs-The Most Common Treatment for Graves’ Disease in the United States: A Nationwide Population-Based Study[J].Thyroid, 2016, 26:1144-1145.
[72] Burch H B 1, Burman K D, Cooper D S.A 2011 survey of clinical practice patterns in the management of Graves’disease[J].J Clin Endocrinol Metab, 2011, 97(12):4549-4558.
[73] Nakanmura H, Noh J Y, Itoh K, et al.Comparison of methimazole and propythiouacil in patients with hyperthyroidism caused by Graves disease[J].J Clin Endocrinol Metabol, 2007, 92:2157-2162.
[74] Sjölin, G, Holmberg,M, Törring O, et al.The Long-Term Outcome of Treatment for Graves'Hyperthyroidism[J].Thyroid, 2019, 29(11):1545-1557.
[75] Lauberg P, Wallin G, Tallstedt L,et al.TSH-receptor autoimmunity in Graves disease after therapy with antithyroid drugs,surgery or radioiodine: A five-year prospective randomized study[J].Eur J Endocrinol, 2008,158:69-75.
[76]中华医学会内分泌学分会， 中华医学会围产医学分会.妊娠和产后甲状腺疾病诊治指南[J].中华内分泌代谢杂志，2019， 25（8）： 636-665.
[77] Rivkees S A, Mattison D R.Propylthiouracil (PTU)Hepatoxicity in Children and Recommendations for Discontinuation of Use[J].Int J Pediatr Endocrinol, 2009,132041.
[78] Wang M T, Lee W J, Huang T Y, et al.Antithyroid drugrelated hepatotoxicity in hyperthyroidism patients: a population-based cohort study[J].Br J Clin Pharmacol,2014, 78(3):619-629.
[79] Yang J 1, Li LF, Xu Q, et al.Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China[J].Thyroid, 2015, 25(3):278-283.
[80] Gao Y, Chen M, Ye H, et al.Long-term outcomes of patients with propylthiouracilinduced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis[J].Rheumatology (Oxford) , 2008,47:1515-1520.
[81]中华医学会核医学分会.131I治疗格雷夫斯甲亢指南（2013版）[J].中华核医学与分子影像杂志，2013，33（2）：83-95.
[82] Singer R B.Long-term comparative cancer mortality after use of radio-iodine in the treatment of hyperthyroidism,a fully reported multicenter study[J].J Insur Med, 2001,33(2):138-142.
[83] Liu Z W, Masterson L, Fish B, et al.Thyroid surgery for Graves’disease and Graves’ophthalmopathy[J].Cochrane Database Syst Rev, 2015,25(11):CD010576.
[84] Sato, Shotaro，Noh, et al.Comparison of Efficacy and Adverse Effects Between Methimazole 15mg+Inorganic Iodine 38mg/Day and Methimazole 30mg/Day as Initial Therapy for Graves’Disease Patients with Moderate to Severe[J].Hyperthyroidism Thyroid, 2015, 25:43-50.
[85] Wiersinga W M.Graves’Disease: Can It Be Cured? [J].Endocrinol Metab (Seoul), 2019, 34(1):29-38.